Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q3 FY20 results · Oct–Dec 2019
Bliss GVS Pharma reported revenue from operations of ₹147.85 crore (down 32.9% from Q3 FY19) and net profit of ₹25.45 crore (down 6.5% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 147.85 | 220.43 | −32.9% | 210.12 | −29.6% |
| Other income | 5.52 | (3.90) | Turned profit | 12.90 | −57.2% |
| Total income | 153.37 | 216.53 | −29.2% | 223.02 | −31.2% |
| Profit before tax | 34.41 | 36.48 | −5.7% | 33.81 | +1.8% |
| Net profit for the period | 25.45 | 27.23 | −6.5% | 30.86 | −17.5% |
| Attributable to shareholders of the company | 23.75 | 25.84 | −8.1% | 30.98 | −23.4% |
| EPS, basic (₹) | 2.30 | 2.50 | −8.0% | 3.00 | −23.3% |
| Net margin (%) | 17.2 | 12.4 | 14.7 |
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 124.82 | 95.63 | +30.5% | 104.00 | +20.0% |
| Other income | 5.61 | (4.35) | Turned profit | 12.29 | −54.3% |
| Total income | 130.43 | 91.28 | +42.9% | 116.30 | +12.2% |
| Profit before tax | 31.56 | 18.27 | +72.7% | 30.50 | +3.5% |
| Net profit for the period | 23.56 | 11.70 | +101.3% | 28.44 | −17.2% |
| EPS, basic (₹) | 2.28 | 1.13 | +101.8% | 2.76 | −17.4% |
| Net margin (%) | 18.9 | 12.2 | 27.3 |
Consolidated
- Filed with BSE
- 13 Feb 2020, 08:59 IST
- Board meeting
- 11 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Feb 2020, 08:59 IST
- Board meeting
- 11 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE